Libya vs Switzerland: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Libya
92.0%
in 2025
Switzerland
92.0%
in 2025
Libya rank
56th
Switzerland rank
56th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Libya
- Switzerland
How they compare
Libya currently reports 92.0% against 92.0% in Switzerland, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Switzerland ahead.
Libya ranks 56th and Switzerland ranks 56th of 194 countries.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Libya | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 19.0% | 19.0% | Switzerland |
| 2010s | 44.6% | 71.6% | 27.0% | Switzerland |
| 2020s | 78.8% | 89.2% | 10.3% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Libya or Switzerland?
- Libya, at 92.0% against 92.0% in Switzerland as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Libya and Switzerland?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and Switzerland?
- 18 years are reported by both, from 2008 to 2025.
- How do Libya and Switzerland rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Libya ranks 56th and Switzerland ranks 56th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.